{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T23:00:48Z","timestamp":1771455648736,"version":"3.50.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,6,30]],"date-time":"2023-06-30T00:00:00Z","timestamp":1688083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,6,30]],"date-time":"2023-06-30T00:00:00Z","timestamp":1688083200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Maxillofac Plast Reconstr Surg"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Denosumab (DMB) is a bone antiresorptive agent used to treat osteoporosis or metastatic cancer of the bones. However, denosumab-associated osteonecrosis of the jaw (DRONJ) has become a common complication in cancer patients. The prevalence of osteonecrosis of the jaw (ONJ) in cancer patients is estimated to be similar for both bisphosphonate-related cases (1.1 to 1.4%) and denosumab-related cases (0.8 to 2%), with the addition of adjunctive therapy with anti-angiogenic agents reportedly increasing its prevalence to 3%. (Spec Care Dentist 36(4):231\u2013236, 2016). The aim of this study is to report on DRONJ in cancer patients treated with DMB (Xgeva\u00ae, 120mg).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Case presentation<\/jats:title>\n                <jats:p>In this study, we identified four cases of ONJ among 74 patients receiving DMB therapy for metastatic cancer. Of the four patients, three had prostate cancer and one had breast cancer. Preceding tooth extraction within 2 months of the last DMB injection was found to be a risk factor for DRONJ. Pathological examination revealed that three patients had acute and chronic inflammation, including actinomycosis colonies. Among the four patients with DRONJ referred to us, three were successfully treated without complications and had no recurrence following surgical treatment, while one did not follow up. After healing, one patient experienced a recurrence at a different site. Sequestrectomy in conjunction with antibiotic therapy and cessation of DMB use proved to be effective in managing the condition, and the ONJ site healed after an average 5-month follow-up period.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Conservative surgery, along with antibiotic therapy and discontinuation of DMB, was found to be effective in managing the condition. Additional studies are needed to investigate the contribution of steroids and anticancer drugs to jaw bone necrosis, the prevalence of multicenter cases, and whether there is any drug interaction with DMB.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s40902-023-00391-9","type":"journal-article","created":{"date-parts":[[2023,6,30]],"date-time":"2023-06-30T09:03:49Z","timestamp":1688115829000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Denosumab-associated jaw bone necrosis in cancer patients: retrospective descriptive case series study"],"prefix":"10.1186","volume":"45","author":[{"given":"Ji-Yeon","family":"Kang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sang-Yup","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jae-Seok","family":"Lim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jwa-Young","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ga-Youn","family":"Jin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yeon-Jung","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0959-3415","authenticated-orcid":false,"given":"Eun-Young","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,6,30]]},"reference":[{"issue":"2","key":"391_CR1","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1007\/s10147-013-0561-6","volume":"19","author":"WX Qi","year":"2014","unstructured":"Qi WX, Tang LN, He AN, Yao Y, Shen Z (2014) Risk of osteonecrosis of the jaw in cancer patients receiving denosumab: a meta-analysis of seven randomized controlled trials. Int J Clin Oncol. 19(2):403\u2013410. https:\/\/doi.org\/10.1007\/s10147-013-0561-6","journal-title":"Int J Clin Oncol."},{"issue":"5 SUPPL.","key":"391_CR2","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.joms.2008.12.004","volume":"67","author":"TB Dodson","year":"2009","unstructured":"Dodson TB (2009) Intravenous bisphosphonate therapy and bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 67(5 SUPPL.):44\u201352. https:\/\/doi.org\/10.1016\/j.joms.2008.12.004","journal-title":"J Oral Maxillofac Surg"},{"issue":"10","key":"391_CR3","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1016\/j.oraloncology.2012.03.028","volume":"48","author":"S K\u00fchl","year":"2012","unstructured":"K\u00fchl S, Walter C, Acham S, Pfeffer R, Lambrecht JT (2012) Bisphosphonate-related osteonecrosis of the jaws - a review. Oral Oncol. 48(10):938\u2013947. https:\/\/doi.org\/10.1016\/j.oraloncology.2012.03.028","journal-title":"Oral Oncol."},{"issue":"5 SUPPL","key":"391_CR4","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.joms.2009.01.009","volume":"67","author":"SL Ruggiero","year":"2009","unstructured":"Ruggiero SL, Dodson TB, Assael LA, Landesberg R, Marx RE, Mehrotra B (2009) American association of oral and maxillofacial surgeons position paper on bisphosphonate-related osteonecrosis of the jaws-2009 update. J Oral Maxillofac Surg 67(5 SUPPL):2\u201312. https:\/\/doi.org\/10.1016\/j.joms.2009.01.009","journal-title":"J Oral Maxillofac Surg"},{"issue":"4","key":"391_CR5","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1111\/adj.12217","volume":"59","author":"M O\u2019Halloran","year":"2014","unstructured":"O\u2019Halloran M, Boyd NM, Smith A (2014) Denosumab and osteonecrosis of the jaws - the pharmacology, pathogenesis and a report of two cases. Aust Dent J. 59(4):516\u2013519. https:\/\/doi.org\/10.1111\/adj.12217","journal-title":"Aust Dent J."},{"issue":"2","key":"391_CR6","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.cden.2013.12.006","volume":"58","author":"J Uyanne","year":"2014","unstructured":"Uyanne J, Calhoun CC, Le AD (2014) Antiresorptive drug-related osteonecrosis of the jaw. Dent Clin North Am. 58(2):369\u2013384. https:\/\/doi.org\/10.1016\/j.cden.2013.12.006","journal-title":"Dent Clin North Am."},{"issue":"3","key":"391_CR7","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.bjoms.2009.08.030","volume":"48","author":"KH Taylor","year":"2010","unstructured":"Taylor KH, Middlefell LS, Mizen KD (2010) Osteonecrosis of the jaws induced by anti-RANK ligand therapy. Br J Oral Maxillofac Surg 48(3):221\u2013223. https:\/\/doi.org\/10.1016\/j.bjoms.2009.08.030","journal-title":"Br J Oral Maxillofac Surg"},{"issue":"4","key":"391_CR8","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.mayocp.2013.01.002","volume":"88","author":"TD Rachner","year":"2013","unstructured":"Rachner TD, Platzbecker U, Felsenberg D, Hofbauer LC (2013) Osteonecrosis of the jaw after osteoporosis therapy with denosumab following long-term bisphosphonate therapy. Mayo Clin Proc. 88(4):418\u2013419. https:\/\/doi.org\/10.1016\/j.mayocp.2013.01.002","journal-title":"Mayo Clin Proc."},{"issue":"5","key":"391_CR9","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1016\/j.joms.2009.10.010","volume":"68","author":"TL Aghaloo","year":"2010","unstructured":"Aghaloo TL, Felsenfeld AL, Tetradis S (2010) Osteonecrosis of the jaw in a patient on denosumab. J Oral Maxillofac Surg 68(5):959\u2013963. https:\/\/doi.org\/10.1016\/j.joms.2009.10.010","journal-title":"J Oral Maxillofac Surg"},{"issue":"10","key":"391_CR10","doi-asserted-by":"publisher","first-page":"672","DOI":"10.12968\/denu.2011.38.10.672","volume":"38","author":"Y Arrain","year":"2011","unstructured":"Arrain Y (2011) A current update on osteonecrosis of the jaw and bisphosphonates. Dent Update 38(10):672\u20136, 678","journal-title":"Dent Update"},{"issue":"3","key":"391_CR11","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/j.joms.2012.07.049","volume":"71","author":"KE Fleisher","year":"2013","unstructured":"Fleisher KE, Jolly A, Venkata UDC, Norman RG, Saxena D, Glickman RS (2013) Osteonecrosis of the jaw onset times are based on the route of bisphosphonate therapy. J Oral Maxillofac Surg 71(3):513\u2013519. https:\/\/doi.org\/10.1016\/j.joms.2012.07.049","journal-title":"J Oral Maxillofac Surg"},{"issue":"6","key":"391_CR12","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/j.oooo.2012.08.439","volume":"114","author":"J Malan","year":"2012","unstructured":"Malan J, Ettinger K, Naumann E, Beirne OR (2012) The relationship of denosumab pharmacology and osteonecrosis of the jaws. Oral Surg Oral Med Oral Pathol Oral Radiol. 114(6):671\u2013676. https:\/\/doi.org\/10.1016\/j.oooo.2012.08.439","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol."},{"issue":"1","key":"391_CR13","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1007\/s00198-010-1177-6","volume":"22","author":"A Kyrgidis","year":"2011","unstructured":"Kyrgidis A, Toulis KA (2011) Denosumab-related osteonecrosis of the jaws. Osteoporosis International. 22(1):369\u2013370. https:\/\/doi.org\/10.1007\/s00198-010-1177-6","journal-title":"Osteoporosis International."},{"issue":"3 SUPPL","key":"391_CR14","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/S1532-3382(12)70046-5","volume":"12","author":"J Yamashita","year":"2012","unstructured":"Yamashita J, McCauley LK (2012) Antiresorptives and osteonecrosis of the jaw. J Evid Based Dent Pract 12(3 SUPPL):233\u2013247. https:\/\/doi.org\/10.1016\/S1532-3382(12)70046-5","journal-title":"J Evid Based Dent Pract"},{"issue":"2","key":"391_CR15","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.oooo.2021.06.003","volume":"133","author":"C Ottesen","year":"2022","unstructured":"Ottesen C, Schiodt M, Jensen SS, Kofod T, Gotfredsen K (2022) Tooth extractions in patients with cancer receiving high-dose antiresorptive medication: a randomized clinical feasibility trial of drug holiday versus drug continuation. Oral Surg Oral Med Oral Pathol Oral Radiol. 133(2):165\u2013173. https:\/\/doi.org\/10.1016\/j.oooo.2021.06.003","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol."},{"issue":"4","key":"391_CR16","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1210\/jc.2010-1502","volume":"96","author":"HG Bone","year":"2011","unstructured":"Bone HG, Bolognese MA, Yuen CK et al (2011) Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass. J Clin Endocrinol Metab 96(4):972\u2013980. https:\/\/doi.org\/10.1210\/jc.2010-1502","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"391_CR17","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1051\/mbcb\/2021035","volume":"27","author":"S Beaudouin","year":"2021","unstructured":"Beaudouin S, Scailteux LM, Lefeuvre C, Gamby R, Cairon-Lejeune S (2021) Jaw osteonecrosis in patients treated with denosumab 120 mg with regular dental monitoring: 4-year retrospective study. J Oral Med Oral Surg 27(4):47","journal-title":"J Oral Med Oral Surg"},{"issue":"5","key":"391_CR18","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1016\/j.oooo.2015.07.017","volume":"120","author":"TM You","year":"2015","unstructured":"You TM, Lee KH, Lee SH, Park W (2015) Denosumab-related osteonecrosis of the jaw: a case report and management based on pharmacokinetics. Oral Surg Oral Med Oral Pathol Oral Radiol. 120(5):548\u2013553. https:\/\/doi.org\/10.1016\/j.oooo.2015.07.017","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol."},{"issue":"12","key":"391_CR19","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1093\/annonc\/mdm370","volume":"18","author":"F Jadu","year":"2007","unstructured":"Jadu F, Lee L, Pharoah M, Reece D, Wang L (2007) A retrospective study assessing the incidence, risk factors and comorbidities of pamidronate-related necrosis of the jaws in multiple myeloma patients. Annals of Oncology. 18(12):2015\u20132019. https:\/\/doi.org\/10.1093\/annonc\/mdm370","journal-title":"Annals of Oncology."},{"issue":"18","key":"391_CR20","first-page":"e671","volume":"94","author":"KN Pilanci","year":"2015","unstructured":"Pilanci KN, Alco G, Ordu C et al (2015) Is administration of trastuzumab an independent risk factor for developing osteonecrosis of the jaw among metastatic breast cancer patients under zoledronic acid treatment? Medicine (United States) 94(18):e671","journal-title":"Medicine (United States)"},{"issue":"4","key":"391_CR21","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1111\/adj.12723","volume":"65","author":"T Manzie","year":"2020","unstructured":"Manzie T, Vujcich N, Chan A (2020) Osteonecrosis of the jaw in an anti-resorptive na\u00efve patient taking trastuzumab and pertuzumab: case report. Aust Dent J. 65(4):305\u2013307. https:\/\/doi.org\/10.1111\/adj.12723","journal-title":"Aust Dent J."},{"issue":"5","key":"391_CR22","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1080\/02841860601185917","volume":"46","author":"C Ortega","year":"2007","unstructured":"Ortega C, Montemurro F, Faggiuolo R et al (2007) Osteonecrosis of the jaw in prostate cancer patients with bone metastases treated with zoledronate: a retrospective analysis. Acta Oncol (Madr). 46(5):664\u2013668. https:\/\/doi.org\/10.1080\/02841860601185917","journal-title":"Acta Oncol (Madr)."},{"issue":"3","key":"391_CR23","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1093\/jnci\/djq516","volume":"103","author":"M Pazianas","year":"2011","unstructured":"Pazianas M (2011) Osteonecrosis of the jaw and the role of macrophages. J Natl Cancer Inst. 103(3):232\u2013240. https:\/\/doi.org\/10.1093\/jnci\/djq516","journal-title":"J Natl Cancer Inst."},{"issue":"1","key":"391_CR24","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.jpor.2014.08.001","volume":"59","author":"K Niibe","year":"2015","unstructured":"Niibe K, Ouchi T, Iwasaki R, Nakagawa T, Horie N (2015) Osteonecrosis of the jaw in patients with dental prostheses being treated with bisphosphonates or denosumab. J Prosthodont Res. 59(1):3\u20135. https:\/\/doi.org\/10.1016\/j.jpor.2014.08.001","journal-title":"J Prosthodont Res."},{"issue":"16","key":"391_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijerph17165998","volume":"17","author":"G Campisi","year":"2020","unstructured":"Campisi G, Mauceri R, Bertoldo F et al (2020) Medication-related osteonecrosis of jaws (MRONJ) prevention and diagnosis: Italian consensus update 2020. Int J Environ Res Public Health. 17(16):1\u201315. https:\/\/doi.org\/10.3390\/ijerph17165998","journal-title":"Int J Environ Res Public Health."},{"issue":"11","key":"391_CR26","doi-asserted-by":"publisher","first-page":"2323","DOI":"10.1007\/s00198-021-05995-3","volume":"32","author":"T Hasegawa","year":"2021","unstructured":"Hasegawa T, Ueda N, Yamada S et al (2021) Denosumab-related osteonecrosis of the jaw after tooth extraction and the effects of a short drug holiday in cancer patients: a multicenter retrospective study. Osteoporosis International. 32(11):2323\u20132333. https:\/\/doi.org\/10.1007\/s00198-021-05995-3","journal-title":"Osteoporosis International."},{"issue":"5","key":"391_CR27","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1016\/j.joms.2022.02.008","volume":"80","author":"SL Ruggiero","year":"2022","unstructured":"Ruggiero SL, Dodson TB, Aghaloo T, Carlson ER, Ward BB, Kademani D (2022) American association of oral and maxillofacial surgeons\u2019 position paper on medication-related osteonecrosis of the jaws\u20142022 update. Journal of Oral and Maxillofacial Surgery. 80(5):920\u2013943. https:\/\/doi.org\/10.1016\/j.joms.2022.02.008","journal-title":"Journal of Oral and Maxillofacial Surgery."},{"issue":"7","key":"391_CR28","doi-asserted-by":"publisher","first-page":"4370","DOI":"10.3390\/app13074370","volume":"13","author":"AM Inchingolo","year":"2023","unstructured":"Inchingolo AM, Malcangi G, Ferrara I et al (2023) MRONJ treatment strategies: a systematic review and two case reports. Appl Sci (Switzerland) 13(7):4370. https:\/\/doi.org\/10.3390\/app13074370","journal-title":"Appl Sci (Switzerland)"},{"issue":"1","key":"391_CR29","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s13005-021-00280-4","volume":"17","author":"G Campisi","year":"2021","unstructured":"Campisi G, Mauceri R, Bertoldo F, Fusco V, Bedogni A (2021) A pragmatic window of opportunity to minimise the risk of MRONJ development in individuals with osteoporosis on Denosumab therapy: a hypothesis. Head Face Med 17(1):25","journal-title":"Head Face Med"},{"issue":"1","key":"391_CR30","doi-asserted-by":"publisher","first-page":"41","DOI":"10.3390\/oral2010006","volume":"2","author":"G Bettini","year":"2022","unstructured":"Bettini G, Saia G, Benetello F, Bedogni A (2022) Temporary denosumab discontinuation promotes bone healing of osteonecrosis of the jaw and minimizes the invasiveness of surgery: a case presentation. Oral. 2(1):41\u201348. https:\/\/doi.org\/10.3390\/oral2010006","journal-title":"Oral."}],"container-title":["Maxillofacial Plastic and Reconstructive Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40902-023-00391-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40902-023-00391-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40902-023-00391-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,30]],"date-time":"2023-06-30T09:03:52Z","timestamp":1688115832000},"score":1,"resource":{"primary":{"URL":"https:\/\/jkamprs.springeropen.com\/articles\/10.1186\/s40902-023-00391-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,30]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["391"],"URL":"https:\/\/doi.org\/10.1186\/s40902-023-00391-9","relation":{},"ISSN":["2288-8586"],"issn-type":[{"value":"2288-8586","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,30]]},"assertion":[{"value":"13 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient for the publication of this case report and accompanying images (IRB No. 2020-06-002-003).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"23"}}